Blockade of the forward \( \text{Na}^+/\text{Ca}^{2+} \) exchanger suppresses the growth of glioblastoma cells through \( \text{Ca}^{2+} \)-mediated cell death

Hui-Jie Hu | Shan-Shan Wang | Yan-Xia Wang | Yan Liu | Xue-Mei Feng | Ying Shen | Liang Zhu | Hong-Zhuang Chen | Mingke Song

Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence
Hong-Zhuang Chen and Mingke Song, Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Rd, Shanghai 200025, China.
Email: yaoli@shsmu.edu.cn; mksong@sjtu.edu.cn

Funding information
Shanghai Jiao Tong University School of Medicine; National Natural Science Foundation of China, Grant/Award Numbers: 81473232, 81671375 and 81873807

Background and Purpose: The \( \text{Na}^+/\text{Ca}^{2+} \) exchanger (NCX) working in either forward or reverse mode participates in maintaining intracellular \( \text{Ca}^{2+} \) ([\( \text{Ca}^{2+} \)]) homeostasis, which is essential for determining cell fate. Previously, numerous blockers targeting reverse or forward NCX have been developed and studied in ischaemic tissue injury but barely examined in glioblastoma for the purpose of anti-tumour therapy. We assessed the effect of NCX blockers on glioblastoma growth and whether NCX can become a therapeutic target.

Experimental Approach: Patch-clamp recording, \( \text{Ca}^{2+} \) imaging, flow cytometry, and Western blot were used to study the effects of specific and non-specific NCX blockers on cultured glioblastoma cells. In vivo bioluminescent imaging was used to measure effects on grafted glioblastoma.

Key Results: Selectively blocking the reverse NCX with SEA0400, SN-6, and YM-244769 did not affect tumour cell viability. Blocking the forward NCX with bepridil, CB-DMB, or KB-R7943 elevated \([\text{Ca}^{2+}]_{i}\]), and killed glioblastoma cells. Bepridil and CB-DMB caused \( \text{Ca}^{2+} \)-dependent cell cycle arrest together with apoptosis, which were all attenuated by a \( \text{Ca}^{2+} \) chelator BAFTA-AM. Systemic administration of bepridil inhibited growth of brain-grafted glioblastoma. Bepridil did not appear to have a cytotoxic effect on human astrocytes, which have higher functional expression of NCX than glioblastoma cells.

Conclusions and Implications: Low expression of the NCX makes glioblastoma cells sensitive to disturbance of \([\text{Ca}^{2+}]_{i}\). Interventions designed to block the forward NCX can cause \( \text{Ca}^{2+} \)-mediated injury to glioblastoma thus having therapeutic potential. Bepridil could be a lead compound for developing new anti-tumour drugs.

Abbreviations: \([\text{Ca}^{2+}]_{i}\), intracellular \( \text{Ca}^{2+} \); BAFTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetraacetoxymethyl ester; BBB, blood–brain barrier; bepridil, N-benzyl-\( \text{N}[\text{4}-\text{isobutyl-2-pyrrolidin-1-y1-propyl}] \)aniline; CB-DMB, \( [\text{N}[\text{4}-\text{chlorobenzyl}]_{2},\text{dimethylbenzamyl}] \); CC-930, tanzisertib; KB-R7943, 2-[4-\( \text{N}[\text{4}-\text{nitrophenyl}]\text{methoxy}]\text{phenyl}][\text{ethyl ester} \text{carbamimidothioic acid methanesulfonate}]; NCX, \( \text{Na}^+/\text{Ca}^{2+} \) exchanger; SEA0400, 2-[4-[2,5-difluorophenyl][methoxy][phenyl]5-ethoxyaniline; SN-6, 2-[4-\( \text{N}[\text{4}-\text{nitrophenyl}]\text{methoxy}][\text{phenyl}][\text{ethyl ester} 4\text{thiazolidinecarboxylic acid ethyl ester}; YM-244769, N-[\text{3-aminophenyl}][\text{methyl}][6-4-\( \text{[3-fluorophenyl][methoxy][phenoxyl]}][\text{3-pyridinecarboxamide dihydrochloride}

Hui-Jie Hu and Shan-Shan Wang contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
1 | INTRODUCTION

Intracellular Ca²⁺ signalling plays an important role in cell fate determination such as quiescence or proliferation, survival, or death and, therefore, is receiving increasing attention in the study of glioblastoma evolution (Leclerc et al., 2016; Morrone, Gehring, & Nicoletti, 2016). Tumor biology studies document that glioblastoma cells release toxic concentrations of glutamate to surrounding neurons (Buckingham et al., 2011; Ye & Sontheimer, 1999). Glutamate constantly activates glutamate receptors in glioblastoma cells and causes Ca²⁺ influx. If Ca²⁺ extrusion mechanisms are inhibited, the intracellular Ca²⁺ ([Ca²⁺]) will build up in glioblastoma cells. The accumulation of [Ca²⁺], is a well-known step that causes ischemic/hypoxic cell death (Dong, Saikumar, Weinberg, & Venkatachalam, 2006; Trump & Berezesky, 1995). An elevation of [Ca²⁺], may also be lethal to tumor cells and become a new approach for combating glioblastoma. However, the data regarding how to induce [Ca²⁺], overload and Ca²⁺-dependent injury in glioblastoma are very limited (Hsu et al., 2016; Liang & Lu, 2012).

The Na⁺/Ca²⁺ exchanger (NCX) is an antiporter located in the plasma membrane. NCX participates in maintaining intracellular Ca²⁺ homeostasis by working either in the forward mode (Ca²⁺ extrusion) or in the reverse mode (Ca²⁺ entry) depending on the membrane potential and the transmembrane Ca²⁺ and Na⁺ concentrations (Giladi, Tal, & Khananshvili, 2016; Nagy et al., 2004). The mammalian NCX (SLC8) family contains three isoforms, NCX1, NCX2, and NCX3. NCX1 predominately exists in neurons, glial cells, cardiomyocytes, and renal tissue, while NCX2–NCX3 barely appear in tissues other than brain and skeletal muscle (Annunziato, Pignataro, & Di Renzo, 2004). NCX and the plasma membrane Ca²⁺-ATPase are the main Ca²⁺ transporters that are in charge of extruding [Ca²⁺], in neurons and glial cells (Blaustein, Juhaszova, Golovina, Church, & Stanley, 2002). The NCX has 20-fold to 60-fold higher Ca²⁺-transporting capacity than plasma membrane Ca²⁺-ATPase (Herchuelz, Kamagate, Ximenes, & Van Eylen, 2007), so NCX is the primary means of Ca²⁺ extrusion when [Ca²⁺] accumulates above the basal level. Inhibition of the NCX occludes the main route of Ca²⁺ extrusion and thus will result in [Ca²⁺], overload. To validate this speculation, we examined whether NCX blockers can elevate [Ca²⁺], in glioblastoma cells and induce Ca²⁺-dependent cell death.

Over the past 20 years, many NCX blockers have been developed and employed to study the pathological role of NCX in hypoxic/ischaemic brain, heart, and renal tissue (Pignataro, Gala, et al., 2004; Shenoda, 2015). Bepridil is often used as a forward NCX blocker in pharmacological studies; however, it also partially inhibits the reverse NCX and affects some K⁺ and Ca²⁺ channels in animal cardiomyocytes (Annunziato et al., 2004; Ma, Takanari, Masuda, Morishima, & Ono, 2016; Wang, Kiyosue, Kiriyama, & Arita, 1999; Watanabe & Kimura, 2001). CB-DMB is a more specific blocker for inhibiting the forward mode of NCX (Amoroso et al., 1997; Annunziato et al., 2004). KB-R7943 is a blocker that inhibits the NCX in both operation modes (Watanabe, Harada, Harada, & Nishimura, 1999). Inhibition of forward NCX by bepridil aggravates ischaemic brain damage, whereas inhibitors that selectively target the reverse NCX, such as SEA0400, SN-6, and YM-244769, produce protection in various hypoxic/ischaemic cell injury models (Hu & Song, 2017; Pignataro, Tortiglione, et al., 2004). Thus, pharmacological effects of NCX blockers rely on what mode of NCX operation is blocked at a given time. Theoretically, inhibition of the reverse NCX impedes NCX-mediated Ca²⁺ entry and reduces Ca²⁺-mediated injury. In contrast, blockade of the forward NCX (Ca²⁺ efflux) will lead to Ca²⁺ accumulation and cytotoxicity. Given that NCX blockers have been well developed and studied, it is timely and of great interest to know what action these NCX blockers will exert on glioblastoma. Particularly, involvement of the NCX in glioblastoma growth has not been well studied using either pharmacological or genetic approaches (Amoroso et al., 1997; Hsu, Chou, & Chueh, 1995).

Here, we showed that blocking reverse NCX with its selective inhibitors does not affect tumour growth; the glioblastoma is only suppressed when the forward NCX is blocked. Blocking the forward NCX is an effective strategy to beat glioblastoma. Therefore, the plasma membrane NCX may represent a new potential therapeutic target.

2 | METHODS

2.1 | Animals and ethical statement

Male athymic BALB/c nude mice were provided by Shanghai Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, China). BALB/c nude mice was developed through crosses and backcrosses...
between BALB/cABom-nu and BALB/cAnNCrj-nu at Charles River Laboratories Japan, Inc.; this mouse is inbred, and genetic monitoring results confirm it to be a BALB/c nude. The animal lacks a thymus, is unable to produce T cells, and is therefore immunodeficient. Mice were housed in the specific pathogen-free animal facility with free access to food and water and a 12-hr light to dark cycle. Mice at 8 weeks of age were chosen for experiments. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the recommendations made by the British Journal of Pharmacology. All animal experimental procedures were approved by the Animal Experimentation Ethics Committee and Institutional Animal Care and Use Committee at Shanghai Jiao Tong University School of Medicine and carried out strictly in accordance with the guideline of Association for Assessment and Accreditation of Laboratory Animal Care. Efforts were made to minimize animals' suffering and to reduce the number of animals used.

2.2 | Culture of glioblastoma cells and astrocytes

Human glioblastoma cell lines U87 (Cat# HTB-14, RRID:CVCL_0022), A172 (Cat# CRL-1620, RRID:CVCL_0131), and U118 (Cat# HTB-15, RRID:CVCL_0633) were from American Type Culture Collection (Rockville, MD, USA). The glioblastoma cell line U251 (Cat# TCHu 58; Zhang et al., 2013) was from the Cell Bank of Type Culture Collection (Rockville, MD, USA). The glioblastoma cell line SF188 (Bender et al., 2013) was kindly provided by Dr Yu-Jie Tang (Shanghai Jiao Tong University School of Medicine, China) and Dr Stefan Pfister (DKFZ, Germany). These cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) containing L-glutamine and 10% FBS (Gibco). U87 cells expressing the firefly luciferase gene (U87-luciferase [U87-Luc], Cat# CBP30189L, RRID:CVCL_US33) were purchased from Nanjing COBIOER biotechnology company (Nanjing, China) and cultured in DMEM + 10% FBS + 1 μg·ml⁻¹ puromycin. They were used at less than 30 passages. Human astrocytes (Cat# 1800) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA) and cultured in human astrocyte medium supplemented with 10% FBS and astrocyte growth supplement. After selecting for astrocytes in passage 1, passages 2–6 of human astrocytes were used for experiments. All cells were maintained at 37°C in an incubator with a humidified atmosphere containing 5% CO₂ and 95% air.

2.3 | Cell viability assay

Cell viability was determined by using a Cell Counting Kit-8 (Dojin-do, Japan). Briefly, cells were harvested from flasks and plated in 96-well cell culture plates at 5 × 10³ per well and cultured overnight. Cells were treated with test reagents for 72 hr. Control cells were treated with cell culture medium and measured at the same time point as treatment groups. CCK-8 solution (10 μl) was added to each well of the 96-well plates, and the cultures were incubated for 30 min at 37°C. Absorbance at 450 nm was measured using an automatic microplate reader (Molecular Devices, San Jose, CA, USA).

2.4 | Whole-cell patch-clamp recording

Whole-cell patch-clamp recording was performed using a Multiclamp 700B amplifier (Molecular Devices, Foster City, CA, USA) at room temperature. Voltage protocols were provided and current recorded via a DigiData-1550B interface (Molecular Devices) controlled by pClamp 10 Software (Molecular Devices, RRID:SCR_011323). The external solution had a pH of 7.4 and contained (mM): 135 NaCl, 1.25 NaH₂PO₄, 1 MgCl₂, 2 CaCl₂, 10 HEPES, 10 glucose, 0.001 tetrodotoxin, 0.02 ouabain, and 0.01 nifedipine. Internal solution consisted of (in mM): 120 CsCl, 20 NaCl, 2 MgCl₂, 13 CaCl₂, 2 Na₂ATP, 20 BAPTA, and 10 HEPES at a pH 7.2. Recording electrodes pulled from borosilicate glass pipettes (Sutter Instrument, Novato, CA, USA) had a fill resistance of 6 and 8 MΩ when filled with the internal solution. Series resistance was compensated by 75–85%. Linear leak and residual capacitance currents were subtracted online using a P/4 protocol of the pClamp 10. For the recording of the membrane currents related to the NCX, cells were held at ~50 mV and depolarized to +60 mV, and then a voltage ramp starting from +60 to ~120 mV was applied for 1,000 ms before returning back to ~50 mV. The reverse and forward NCX currents were measured at +50 and ~110 mV holding potentials respectively (Molinaro et al., 2008; Rahman, Inman, Kiss, & Janssen, 2012; Song, Chen, & Yu, 2014). Data were filtered at 3 KHz and digitized at sampling rates of 20 KHz. For drug application, cells were perfused with a VC-6 Six Channel Perfusion Valve Control Systems (Warner Instruments, Greenwich, CT, USA) connected to a gravity-fed perfusion systems.

2.5 | Ca²⁺ and Na⁺ imaging

Cells were cultured in 96-well plates at 8 × 10³ per well and loaded with the cell membrane-permeable Ca²⁺ dye Fluo-4 AM (5 μM) in 100-μl HEPES-buffered solution for 50 min. The solution contained (mM): 135 NaCl, 3 KCl, 2 CaCl₂, 1 MgCl₂, 10 glucose, and 10 HEPES, supplemented with 1% FBS at pH 7.4. To prepare the Ca²⁺-free solution, 2-mM CaCl₂ was replaced with 1-mM EGTA in the HEPES-buffered solution. The 96-well plate containing the Fluo-4 AM-loaded cells was mounted in a Leica TCS SP8 confocal system (Leica Microsystems, Wetzlar, Germany). The confocal microscope armed with 488-nm laser light was employed to excite the dynamic fluorescence signals in time and synchronously, while test reagents were added to cells. To do Na⁺ imaging, Fluo-4 AM was replaced with the cell membrane-permeable Na⁺ dye Asante NaTrium Green-2 AM (ANG-2 AM) at 5 μM, which was excited by 514-nm laser light. Visual inspection and fluorescent imaging were carried out at room temperature. The imaging data were analysed with the software LAS-AF-Lite 2.5 (Leica). The imaging traces shown are representative of at least three separate experiments; 12–18 cells were imaged in each experiment.
2.6 | Cell cycle and apoptosis assay

U87 cells were seeded in six-well plates (Corning, Corning, NY, USA) with $1 \times 10^6$ cells per well and treated with NCX blockers, BAPTA-AM, or MAPK inhibitors. Drug treatment was performed by the person who is blinded to the experimental groups. After treatment, cells were harvested in 15-ml tubes and washed with cold sterile PBS. After being centrifuged, cells were fixed with 70% ethanol for 30 min at 4°C for at least 1 hr. For propidium iodide (PI) staining, cells were washed once with PBS and then were treated with ribonuclease A (RNase; 100 μg·ml$^{-1}$) for 30 min. PI (10 μg·ml$^{-1}$) was added, and stained cells were kept in the dark at 4°C until analysis. The number of cells analysed for each sample was 10,000 events. FACS analysis was performed using the Coulter CytoFlexS flow cytometer (Beckman Coulter, CA, USA), and the percentage of cells in the G0/G1, S, and G2/M phases was determined using cell cycle analysis software, ModFit LT 5.0 (Verity Software House, Topsham, ME, USA). For the apoptosis assay, cells were harvested and washed twice with cold PBS and resuspended at a density of $1 \times 10^6$ cells·ml$^{-1}$ in 100 μl of binding buffer containing 5 μl of Annexin V–FITC and 5 μl of PI working solution (100 μg·ml$^{-1}$). After incubation at room temperature for 15 min in the dark, 400 μl of binding buffer was added to each sample. Apoptosis was analysed by Coulter CytoFlexS flow cytometer (Beckman Coulter) for at least 10,000 events, and data were analysed with the software, CyExpert 2.0 (Beckman Coulter).

2.7 | Western blot analysis

After treatment with bepridil for 0, 30, 60, and 90 min, cells were collected and lysed in RIPA buffer (Beyotime, Nanjing, China) supplemented with protease inhibitor (Beyotime). The total protein concentration of each sample was determined using the BCA Protein Assay Kit (Sangon Biotech, Shanghai, China). Equal protein extracts (45-μg protein per lane) were separated by SDS-PAGE and electrophoretically transferred to PVDF membranes (Millipore, Bedford, MA, USA). Then, the membranes were incubated with anti-phosphorylated and total ERK, JNK, and p38-MAPK antibodies (1:1,000; Cell Signaling Technology) at 4°C overnight, followed by incubation with IRDye 680LT fluorescent secondary antibody (LI-COR Biosciences, Lincoln, NE, USA). Proteins were visualized using the Odyssey Fc Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Mouse α-tubulin antibody was used as protein loading controls. The immuno-related procedures used comply with the recommendations made by the British Journal of Pharmacology (Alexander et al., 2018).

2.8 | Nucleoprotein extraction

Adherent cells were washed twice with 10 ml Dulbecco’s PBS. Then 1-mM PMSF, 1-mM DTT, and 10-μl protease inhibitor cocktail (without EDTA) per 1 ml of hypotonic buffer, mix hypotonic buffer, were added and samples placed on ice for a few minutes. After which 0.6-ml mixed hypotonic buffer was added per 10,000,000 cells, on ice, then cells scraped off, and samples transferred to 1.5-ml EP tube, centrifuged for 5 min (4°C, 835×g), and the supernatant removed. The cell lysates were resuspended by adding 0.6-ml hypotonic buffer, centrifuged for 5 min (4°C, 835×g), and the supernatant removed. The pellet was resuspended in 0.3 ml of lysis buffer (lysis buffer contained 1-mM PMSF, 1-mM DTT, and 10-μl protease inhibitor cocktail per 1 ml of lysis buffer), incubated on ice for 20 min, and centrifuged for 10 min (4°C, 13,362×g). The supernatant was nuclear protein extraction.

2.9 | U87-luciferase xenograft model and treatment

The athymic BALB/c nude mice were anaesthetized by subjecting them to 3% isoflurane (RWD Life Science, Shenzhen, China) in a mixture of 30% O2 and 70% N2O. After induction of anaesthesia, 1.5% isoflurane was maintained, and body temperature was kept at $37 \pm 0.5°C$ by a heating pad. The mouse head was maintained within a stereotactic frame (RWD Life Science), allowing a precise and reproducible injection. The coordinate of the injection site was 0.5 mm anterior and 2.5 mm right from the bregma and at a depth of 3 mm. U87-Luc cells (COBIOER) were assessed by the trypsin blue exclusion assay. Only cell suspensions with greater than 95% viability were used and implanted into the right striatum of nude mice. U87-Luc cells (5 $\times$ $10^5$ in 5-μl PBS) were inoculated into the right striatum of each mouse at a controlled flow rate of 0.5 μl-min$^{-1}$, and the total injection volume was about 5 μl. Sixteen days after implantation, the mice were randomly divided into two groups: treated with vehicle ($n = 5$) and treated with bepridil ($n = 5$). Bepridil was first dissolved in ethanol (final volume 5%) and then added to a mixture of polyethylene glycol (50%) and 0.9% NaCl (45%). Mice received bepridil (50 mg·kg$^{-1}$ body weight) or vehicle treatment once a day via oral gavage for 14 days. Drug treatment was performed by a person who was blinded to the experimental groups.

2.10 | MS analysis

Athymic BALB/c nude mice were administered bepridil by oral gavage at doses of 50 mg·kg$^{-1}$ as described above. Two hours later, mice were killed, and the brain sample was homogenized using the tissue homogenizers (Bertin Instruments, Paris, France) in ice-cold deionized water at a concentration of 3 ml·g$^{-1}$ tissue. Then, methanol with 0.1% formic acid was added to the brain homogenate in a 4:1 proportion (vol/vol) and centrifuged at 18,188×g and 4°C for 10 min to precipitate protein. The supernatant was transferred to a vial to be injected directly into the LC-MS. The chromatographic system consisted of Shimadzu quaternary pump, vacuum degasser, and autosampler (Shimadzu, LC-20ADXR, Tokyo, Japan) coupled to triple quad LC-MS systems, API-4000 mass spectrometer (SCIEX, Redwood City, CA, USA). HPLC separation was performed on a Thermo Synchrois C8 column 100 × 2.1 mm, 5.0 μm. The mobile phase consisted of
methanol (A) and water with 0.1% formic acid (B), measure time was 9 min per run. A flow rate of 0.3 ml·min\(^{-1}\) was used using a gradient elution of 70% B at 1 min and 5–70% B between 1 and 5 min and maintained for 2 min at 5% B and back to 70% B at 7–7.1 min. An API-4000 mass spectrometer equipped with ion spray source was employed for obtaining mass spectra. Data acquisition was carried out by analysis software. Ion spray voltage was set at 5,500 V. Curtain gas was kept at 35 psi. Ion source temperature was 550°C. Nebulizing gas and drying gas were at 50 psi. Multiple reaction monitoring mode was utilized to detect the compound of interest. Collision energy (CE) is an instrument parameter that is frequently optimized to increase fragment ion intensity. An alternative to empirically optimizing the CE for bepridil is to predict the best CE value based on the precursor mass-to-charge ratio of bepridil (\(m/z\)). The CE for bepridil was optimized to 30 V. The precursor-to-product ions (Q1 → Q3) selected for bepridil during quantitative optimization were (\(m/z\)) 367.1 → 84.3/184.3.

2.11 | In vivo bioluminescent imaging

Tumours were measured by bioluminescence using an IVIS Spectrum CT Imaging System (PerkinElmer, Waltham, MA, USA), which captured the luminescence signal emitted from the engrafted tumour. Prior to imaging, the mice were anaesthetized with inhalation of isoflurane gas (RWD Life Science) and injected i.p. with 150 mg·kg\(^{-1}\) D-luciferin potassium (J&K Scientific) aqueous solution. The isoflurane was balanced with oxygen and dialled to 2.0% for the induction of anaesthesia and 1.0% for maintenance. Images were subsequently captured 10 min following injection. Signal intensity was quantified within a region of interested over the head, as defined by Living Image software. All images represent 2-min exposure time, and the average number of photons·s\(^{-1}\)·cm\(^{-2}\) per steradian were recorded. The data were analysed using Living Image 4.4.5 software (PerkinElmer, RRID: SCR_014247).

2.12 | Data and statistical analysis

Data are expressed as mean ± SEM and analysed by Prism 7 software, La Jolla, CA (GraphPad Prism, RRID:SCR_002798). The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology. Concentrations of the NCX blockers (IC\(_{50}\)) exerting half-maximal inhibition of NCX currents were obtained by fitting the concentration–response with the equation: \(I/I_0 = 100\% = \text{Top} - \text{Bottom}/(1 + 10^{(\log_{10} C - \text{C})*n})\), where \(I_0\) and \(I\) are current amplitudes measured in control and in the presence of NCX blockers, \(C\) is the logarithm of concentration, and \(n\) is the Hill coefficient. The statistical difference between two independent groups was analysed by Student’s parametric unpaired t test. And the original data of more than two groups were assessed by the parametric one-way ANOVA followed by a Tukey’s post hoc test. The data for cell viability and

**FIGURE 1** Recording and blockade of the Na\(^+\)/Ca\(^{2+}\) exchanger (NCX) currents in glioblastoma cells. (a) Human glioblastoma U87 cells were held at −50 mV; the membrane currents associated with NCX were recorded by a voltage ramp from +60 to −120 mV. Ni\(^{2+}\) (10 mM) was used to block the NCX currents. (b, c) NCX currents recorded before and after application of bepridil (0.1–100 μM) or KB-R7943 (0.1–100 μM). (d–f) The currents recorded before and after application of the reverse NCX blockers SEA0400 (0.1–100 μM), SN-6 (0.1–30 μM), and YM244769 (0.1–30 μM). The reverse NCX current was measured at +50 mV, and forward NCX current was measured at −110 mV.
Western blot were usually normalized to the control group, and were thus analysed by the non-parametric Kruskal–Wallis test followed by a Dunn’s post hoc test. Differences were considered to be significant when $P < .05$. Post hoc tests were conducted when the $F$ value achieved the necessary level ($P < .05$) and there was no significant variance inhomogeneity.

2.13 Materials

[1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM)] (Cat# 2787), YM-244769 (Cat# 4544), KB-R7943 (Cat# 1244), SN-6 (Cat# 2184), SEA0400 (Cat# 6164), and bepridil (Cat# 4117) were purchased from Tocris Bioscience (Minneapolis, MN, USA). They were dissolved in DMSO to make a stock solution. Cell Counting Kit-8 and Annexin V–FITC/PI Apoptosis Detection Kit were purchased from Dojindo Laboratories (Tokyo, Japan). Pyridinium iodide was purchased from Sigma-Aldrich (St. Louis, MO, USA). Cell-permeable Fluo-4 AM was purchased from Invitrogen Life Technologies (Walhatham, MA, USA). The primary antibodies for phosphorylated and total ERK (Cat# 8544 and 4348), JNK (Cat# 9251 and 9252), and p38-MAPK (Cat# 9211 and 9212) were all purchased from Cell Signaling Technology (Boston, MA, USA). Anti-NCX1 antibody (Cat# ab177952, RRID:AB_2801276) was purchased from Abcam (Cambridge, MA, USA), and anti-NCX2 (Cat# ANX-012, RRID:AB_2341022) and NCX3 (Cat# ANX-013, RRID:AB_2341023) antibodies were purchased from Alomone Labs (Jerusalem, Israel). β-Luciferin potassium salt was purchased from J&K Scientific (Shenzhen, China).

2.14 Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017; Alexander, Kelly et al., 2017).

| Table 1 | Concentration of compounds required to produce half-maximal inhibition (IC50: μM) of the currents related to the reverse and forward NCX operation |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Compound | blocking reverse NCX | blocking forward NCX | n |
| Bepridil | 15.6 ± 1.1 | 19.1 ± 1.2 | 4 |
| KB-R7943 | 14.3 ± 1.2 | 32.3 ± 1.3 | 4 |
| SEA0400 | 3.6 ± 1.2 | — | 4 |
| SN-6 | 3.2 ± 1.2 | — | 4 |
| YM244769 | 4.5 ± 1.1 | — | 4 |

Note. The values of IC50 (mean ± SEM) were obtained by fitting the concentration-response with the equation: $I/I_0*100\% = \text{Bottom} + (\text{Top} - \text{Bottom})/(1 + 10^{(IC50 - C)/n})$, where $I_0$ and $I$ are current amplitudes measured in control and in the presence of NCX blockers, $C$ is the logarithm of concentration, and $n$ is the Hill coefficient. $n = 4$ independent tests for each compound.

Abbreviation: NCX, Na+/Ca2+ exchanger.

FIGURE 2 Effect of the Na+/Ca2+ exchanger (NCX) blockers on viability of human glioblastoma cell lines. (a, b) Viability of adult glioblastoma cell lines (U87 and U251) after exposure to NCX blockers bepridil, KB-R7943, SEA0400, SN-6, or YM244769 at 0–100 μM for 72 hr. n = 5 independent tests per group. (c) Viability of paediatric glioblastoma cell line SF188 after 72-hr incubation with the same NCX blockers at 0–100 μM. n = 5 independent tests per group. (d) For U87, U251, and SF188 cell lines, concentration of the NCX blockers required to produce half maximal inhibition (IC50: μM, mean ± SEM) of cell viability. IC50 was obtained by fitting the normalized concentration–response relation to the equation: $V/V_0 = 1/(1 + [C/IC50]^{n})$, where $V_0$ and $V$ are the cell viability measured in control and in the presence of a blocker, $C$ is the concentration of the blocker, and $n$ is the Hill coefficient. $n = 5$ independent cultures in each group
3 | RESULTS

3.1 | Inhibition of the Na⁺/Ca²⁺ exchanger by its blockers in glioblastoma cells

We characterized the membrane currents associated with NCX activity in glioblastoma cells using whole-cell patch-clamp recording. As illustrated in Figure 1a, cell membrane potential was held at −50 mV, and the NCX currents were elicited by a voltage ramp from +60 to −120 mV. The NCX current in its reverse mode (Ca²⁺ entry) was measured at +50, and the forward-mode current (Ca²⁺ exit) was measured at −110 mV. The Ni²⁺ (10 mM) was employed to inhibit and identify the NCX currents in its either reverse or forward mode as previously reported (Maack, Ganesan, Sidor, & O’Rourke, 2005). The reversal potential of NCX current is around −60 mV determined by intersection of current–voltage relation (I/V) in the absence and presence of...
Bepridil has been reported to block forward-mode NCX and also partially inhibits its reverse mode (Annunziato et al., 2004). We found bepridil blocked both direction of NCX currents in U87 cells, with half-maximal inhibition (IC₅₀) values of 19.1 ± 1.2 and 15.6 ± 1.1 μM (Figure 1b and Table 1). KB-R7943 preferentially inhibits the reverse NCX, and it also blocks the forward NCX (Annunziato et al., 2004). We found KB-R7943 inhibited the reverse NCX currents with an IC₅₀ value of 14.3 ± 1.2 μM, while suppressed its forward currents with an IC₅₀ = 32.3 ± 1.3 μM (Figure 1c and Table 1). SEA0400, SN-6, and YM244769 have good selectivity for the reverse NCX (Figure 1d–f). They selectively block the reverse mode currents of NCX with IC₅₀ values of 3.6 ± 1.2, 3.2 ± 1.2, and 4.5 ± 1.1 μM, without inhibition of the forward NCX currents.

### 3.2 Blocking the forward NCX operation generates cytotoxicity in glioblastoma cells

We next examined impact of NCX blockers on viability of glioblastoma cells. U87 and U251 cell lines were treated with bepridil or KB-R7943

![Graph](image)

**FIGURE 4** Bepridil caused cell cycle arrest and apoptosis in glioblastoma cells. (a, b) Cell cycle assay of U87 cells incubated with bepridil (25 μM) for 6, 12, 18, and 24 hr. Cell fractions in each phase were from cell cycle analysis; bepridil increased the proportion of cells in G₀/G₁ phase and reduced cell fraction in S phase in a time-dependent manner. (c) Cells were pretreated with BAPTA-AM (10 μM) for 18 hr and then incubated with bepridil (25 μM) for 18 hr. BAPTA-AM alone did not incur cell fraction changes but significantly attenuated bepridil-induced cell cycle arrest. *P < .05, G₀/G₁ phase of BAPTA-AM + bepridil versus bepridil alone; n = 5 independent experiments. (d, e) U87 cells were treated with bepridil (25 μM) for 6, 12, 24, and 48 hr and then analysed with Annexin V–FITC/PI apoptosis assay. Bepridil incurred a time-dependent increase of apoptotic cells (Annexin V). (f) Cells were pretreated with BAPTA-AM (10 μM) for 18 hr and then incubated with bepridil (25 μM) for 24 hr. BAPTA-AM significantly suppressed bepridil-induced apoptosis. n = 5 independent experiments; *P < .05, apoptotic cell fraction in BAPTA-AM + bepridil versus bepridil alone, with the parametric one-way ANOVA followed by Tukey’s post hoc test.
We found that viability of U87 and U251 cells was reduced to 30–40%, 6–7%, and 3–4% of control level by 20-, 50-, and 100-μM bepridil (Figure 2a,b). Similarly, U87 and U251 cells were regressed to 50–60%, 7–18%, and 2–3% of control level by 20-, 50-, and 100-μM KB-R7943. Figure 2d lists IC50 values of bepridil and KB-R7943 that cause cytotoxicity. Since bepridil and KB-R7943 inhibit both forward and reverse NCX, we need to clarify whether this cytotoxicity resulted from blocking the reverse or forward NCX operation.

To do so, three inhibitors (SEA0400, SN-6, and YM244769) selective for the reverse NCX were incubated with U87 and U251 cells at 5, 10, 20, 50, and 100 μM for 72 hr. We found that they exert much less impact on glioblastoma cells (Figure 2a,b). SEA0400 at 10, 20, and 50 μM modulated U87 and U251 cell viability to 93–106%, 88–103%, and 72–92% of control level. SN-6 at 10, 20, and 50 μM modulated U87 and U251 cells to of 87–97%, 86–99%, and 74–104% of control level. So, the growth of glioblastoma cells is not affected when the reverse NCX is blocked.

We also applied NCX blockers to a paediatric glioblastoma cell line SF188. These cells were suppressed by bepridil and KB-R7943 in a dose-dependent manner but slightly affected by the compounds that selectively block the reverse NCX (Figure 2c). CB-DMB is a more specific blocker for the forward NCX than bepridil and KB-R7943. It is very exciting to find that CB-DMB is more potent than bepridil and KB-R7943 in suppressing glioblastoma cells (Figure S1a). The IC50 values of CB-DMB that cause cytotoxicity in U87, U251, and SF188 are 3.1 ± 0.6, 2.7 ± 0.1, and 2.6 ± 0.1 μM. These data confirm that blocking the forward but not reverse mode of NCX can suppress the growth of glioblastoma cells.

**FIGURE 5** KB-R7943 caused cell cycle arrest and apoptosis in glioblastoma cells. (a) U87 cells were incubated with 0.1% DMSO (vol/vol), BAPTA-AM (10 μM), KB-R7943 (25 μM), and BAPTA-AM + KB-R7943 for 18 hr and then underwent cell cycle analysis. (b) U87 cells underwent an apoptosis assay after incubation with 0.1% DMSO, 10-μM BAPTA-AM, 25-μM KB-R7943, and BAPTA-AM + KB-R7943 for 20 hr. (c) Cell fractions in G0/G1, S, and G2/M phases of each group. KB-R7943-induced G0/G1 arrest was not rescued by BAPTA-AM. n = 5 independent experiments; data were analysed by one-way ANOVA. (d) Percentage of apoptotic cells in each group. KB-R7943-induced apoptosis was not attenuated by BAPTA-AM. n = 5 independent experiments; data were analysed by one-way ANOVA.
3.3 | Bepridil, CB-DMB, and KB-R7943 elevate [Ca^{2+}], level in glioblastoma cells

We examined influence of NCX blockers on [Ca^{2+}], level in glioblastoma cells. U87 cells were pre-loaded with Fluo-4 and then perfused with bepridil or KB-R7943 in the solution containing 2 mM Ca^{2+} and 1% FBS. Shortly after flush with bepridil, U87 cells showed a quick [Ca^{2+}] increase and sustained [Ca^{2+}] elevation (Figure 3a). KB-R7943 induced two phases of [Ca^{2+}] change: a short [Ca^{2+}] descent in the beginning and a slow [Ca^{2+}] increase ensuing (Figure 3b). To identify the source of bepridil and KB-R7943-induced [Ca^{2+}] increase, we conducted the same Ca^{2+} imaging experiment in a Ca^{2+}-free solution. After perfusion with bepridil or KB-R7943 (Figure 3c), glioblastoma cells did not show [Ca^{2+}] elevation or fluctuation as that occurs in the solution containing Ca^{2+}. Figure 3d shows that after bepridil or KB-R7943, thapsigargin induced Ca^{2+} release from the endoplasmic reticulum (ER) in the Ca^{2+}-free solution. These data indicate that neither bepridil nor KB-R7943 affect intracellular Ca^{2+} pool and Ca^{2+} transporting on the ER membrane.

Figure 3e shows that pretreated with Ca^{2+} chelator, BAPTA-AM (20 μM) completely abrogated the influence of bepridil and KB-R7943 on [Ca^{2+}]. Similarly, CB-DMB elevated [Ca^{2+}], in the Ca^{2+}-containing solution and did not affect the ER Ca^{2+} transporters (Figure S1b-d). The Na+ imaging experiment with Na+ indicator AsanteNaTRIUM Green™ 2 (ANG-2) shows that bepridil and CB-DMB did not change the level of intracellular Na+ [Na+]i, while KB-R7943 slightly decreased [Na+]i, (Figure S2a-c). Finally, there are no detectable NCX isoforms in the nuclei of U87 cells (Figure S2d). Bepridil, CB-DMB, and KB-R7943 all block the forward NCX on cell membrane; this blockage occludes NCX-mediated Ca^{2+} exit. On the other hand, extracellular Ca^{2+} can still enter a cell through other Ca^{2+}-permeable channels, leading to accumulation of [Ca^{2+}]. The transient drop of [Ca^{2+}], caused by KB-R7943 may result from its blocking action on glutamate receptor channels as previously reported (Brustovetsky et al., 2011).

3.4 | Bepridil, CB-DMB, and KB-R7943 cause cell cycle arrest and apoptosis

To do cell cycle analysis, U87 cell cultures were treated with 25-μM bepridil for 6, 12, 18, and 24 hr and stained with PI. We show that bepridil reduced the cell fraction in S phase and increased cells in G0/G1 phase in a time-dependent manner (Figure 4a,b). To determine the role of [Ca^{2+}] in bepridil-induced G0/G1 arrest, BAPTA-AM was used to prevent [Ca^{2+}] accumulation in U87 cells. Figure 4c shows that BAPTA-AM (10 μM) alone for 18 hr did not incur significant cell fraction changes in G0/G1, S and G2/M phases. Bepridil (25 μM, 18 hr) markedly increased cell fraction in G0/G1 phase. This G0/G1 arresting effect was significantly attenuated by 10-μM BAPTA-AM (Figure 4c). To detect any apoptotic cell death involved, U87 cells were treated with bepridil (25 μM) for 6, 12, 24, and 48 hr and then analysed with Annexin V–FITC/PI apoptosis assay. Figure 4d,e shows that bepridil incurred a time-dependent increase of apoptotic (Annexin V+) cells. BAPTA-AM (10 μM) alone for 18 hr did not increase apoptosis in U87 cells but significantly attenuated bepridil-induced apoptosis (Figure 4f). Application of CB-DMB (3.5 μM) to U87 cells also induced G0/G1 arrest and activated apoptosis in time-dependent manner (Figure S3a,d–e), and these cell death processes were significantly attenuated by BAPTA-AM (Figure 3c,f). These data indicate that bepridil and CB-DMB generate cytotoxicity through Ca^{2+}-mediated cell cycle arrest and apoptosis in glioblastoma cells.

KB-R7943 also caused G0/G1 arrest and apoptosis in U87 cells, but Ca^{2+} chelator BAPTA-AM cannot suppress these cell death processes (Figure 5a–d). We notice that KB-R7943 is not a pure NCX blocker (Cheng, Zhang, Du, Dempsey, & Hancox, 2012); it also inhibits ionotropic glutamate NMDA receptors and mitochondrial respiratory complex 1 (Brustovetsky et al., 2011). KB-R7943-induced cytotoxicity does not simply result from NCX inhibition and [Ca^{2+}] elevation. Inhibition of respiratory chain complex 1 impairs mitochondrial oxidative phosphorylation and results in energy deficiency, which might contribute to the cytotoxicity of KB-R7943. Pharmacological action of KB-R7943 in this and past studies may need revisiting and re-evaluation in future.

3.5 | Involvement of MAPK signalling in bepridil-induced cell death

The above data indicate that bepridil killed glioblastoma cells via blockade of the forward NCX and elevation of [Ca^{2+}]. It is well known that [Ca^{2+}], regulates the MAPK signalling pathway, which plays essential role in cell fate determination (White & Sacks, 2010). We here measured the activities of ERK, p38-MAPK, and JNK in U87 cells at the time points

![FIGURE 6](image-url)
10, 30, 60, and 90 min after incubation with 25-μM bepridil. Western blot analysis shows that ERK activity was not affected, but p38-MAPK and JNK were activated by bepridil throughout the selected time points (Figure 6a). To examine the role of [Ca\(^{2+}\)]\text{in}, bepridil-induced MAPK activation, cells were pretreated with Ca\(^{2+}\) chelator BAPTA-AM (10 μM) for 18 hr and then exposure to bepridil (25 μM) for 30 min. Figure 6b shows

![Figure 6a](image)

![Figure 6b](image)

**FIGURE 7** Involvement of MAPK signalling in bepridil-induced cell cycle arrest and apoptosis. (a) Top panel, U87 cells were treated with DMSO (0.1/%, vol/vol), CC-930 (10 μM), and PD169316 (10 μM) for 18 hr. Lower panel, cells were treated with bepridil (25 μM) alone or pretreated with CC-930 (10 μM) and PD169316 (10 μM) for 2 hr and then incubated with bepridil for 18 hr. (b) Cell fractions in G0/G1, S, and G2/M phases of each group. Bepridil-induced G0/G1 cell cycle arrest was rescued by PD169316 but not CC-930. *P < .05, cell fraction in G0/G1 phase of PD169316 + bepridil-treated group versus bepridil-treated group. n = 5 independent experiments; data were analysed by one-way ANOVA. (c, d) CC-930 (10 μM) or PD169316 (10 μM) alone did not increase apoptosis in U87 cells. Cells were pretreated with CC-930 or PD169316 for 2 hr and then incubated with bepridil (25 μM) for 24 hr; only CC-930 significantly suppressed bepridil-induced apoptosis. *P < .05, apoptotic cell fraction in CC-930 + bepridil group versus bepridil group. n = 5 independent experiments; data were analysed by one-way ANOVA.
that activity of the p38-MAPK and JNK was increased by bepridil, and this effect was attenuated by BAPTA-AM pretreatment.

We next investigated whether p38-MAPK and JNK signalling were involved in bepridil-induced cell death. A JNK inhibitor tanzisertib (CC-930) and a p38-MAPK inhibitor PD169316 were dissolved in DMSO to make stock solutions. Flow cytometry analysis shows that U87 cells treated with vehicle (0.1% DMSO, vol/vol), CC-930 (10 μM), or PD169316 (10 μM) had similar cell distribution in each phase of the cell cycle, while bepridil (25 μM) incurred G0/G1 cell cycle arrest (Figure 7a,b). This arresting effect was prevented by PD169316 but not CC-930, indicating that the p38-MAPK signalling is involved in bepridil-induced cell cycle arrest. The Annexin V apoptosis assay demonstrates that CC-930 and PD169316 did not activate apoptosis (Figure 7c,d). Bepridil (25 μM) increased the percentage of apoptotic cells after 24-hr incubation. This effect was attenuated by CC-930 but not PD169316, indicating that the JNK signalling is involved in bepridil-induced apoptosis.

3.6 Functional expression of NCX isoforms and impact of bepridil on human astrocytes

Glioblastoma arises from glial cells in the brain (Ostrom, Gittleman, Stetson, Virk, & Barnholtz-Sloan, 2018). Bepridil was previously applied by Johnson & Johnson Pharmaceutical Research for the treatment of angina and hypertension. We here assessed viability of human astrocytes after exposed to bepridil (25 μM) for 48 hr and compared it with glioblastoma cells. Bepridil did not generate apparent cytotoxicity in human astrocytes, meanwhile markedly suppressed growth of U87, U251, and SF188 cells (Figure 8a). To explore why human astrocyte is not sensitive to NCX blocker bepridil, we measured expression of three NCX isoforms in astrocytes and glioblastoma cells. Western blot analysis shows that NCX1 expression is significantly higher in human astrocytes than glioblastoma cells (Figure 8b). But the level of NCX2 and NCX3 is lower in human astrocytes than glioblastoma cells (Figure 8b).
not high; especially, NCX2 is even lower than that in glioblastoma cells. This observation is identical to the literature, documenting that in astrocytes, NCX1 is the most highly expressed among the three NCX isoforms (Boscia et al., 2016; Pappalardo, Samad, Black, & Waxman, 2014). We then decided to compare the activity of NCX among them by using whole-cell patch-clamp recording. The amplitude of the NCX currents in human astrocytes is much larger than glioblastoma cells (Figure 8c). After performing a calculation, we show current density of the NCX in human astrocytes is several-fold higher than that in glioblastoma cells (Table S1). This high NCX activity and astrocyte’s resistance to bepridil’s toxicity most likely result from high expression of NCX1 isoform. On the other, KB-R7943 is deleterious to astrocytes probably due to its multiple actions besides blocking NCX (Figure 8d).

**FIGURE 9** Bepridil crosses the BBB and inhibits growth of brain-grafted glioblastoma. (a) Dotted box indicates the precursor to product ions (Q1 → Q3) selected for bepridil during quantitative optimization: 367.1 → 84.3 and 367.1 → 184.3 in positive ion mode. (b) Typical chromatogram of brain homogenate sample collected at 2 hr following systemic administration of bepridil (50 mg·kg⁻¹, p.o.). (c, d) Bioluminescent images of U87-luciferase glioblastoma cells implanted into the right cerebral striatum of nude mice. Images were taken by an IVIS Spectrum CT Imaging System before and after the period of treatment with bepridil or vehicle as described in methods. (e) Tumour size determined by bioluminescence and caliper measurement in each group before and after treatment. *P < .05, comparison between the two groups; n = 5 mice per group, analysed by Student’s parametric unpaired t test.
3.7  |  Bepridil inhibits growth of brain-grafted tumour cells in vivo

Bepridil has been shown to be able to penetrate the blood–brain barrier (BBB) and reach the brain after oral administration or intraperitoneal injection at 50 mg·kg⁻¹ body weight in two separate animal studies (Lipsanen et al., 2013; Mitterreiter et al., 2010). Our M5 experiment shows that bepridil can cross the BBB and get into brain tissue (Figure 9a,b) after oral administration. We then tested the effect of bepridil on the growth of established glioblastoma U87-Luc xenografts. U87-Luc cells were stereotactically injected into the right striatum of male nude mice. Sixteen days after intracranial implantation, bepridil (50 mg·kg⁻¹, p.o.) was administered once a day for 14 days. Control group received the same amount of vehicle treatment. Bioluminescent imaging of U87-Luc cells in live mice brain was performed before treatment began and after treatment finished. Tumour size was determined through quantitative bioluminescence of live cells expressing luciferase under the IVIS Spectrum CT Imaging System. Vehicle treatment cannot hamper increasing tumour size, while bepridil successfully restrained tumour growth, yielding a significant volume difference between two groups (Figure 9c-e). So, bepridil is also effective in suppressing growth of glioblastoma in vivo.

4  |  DISCUSSION AND CONCLUSION

The Ca²⁺ signalling in glioblastoma cells attracts increasing attention, and blockade of Ca²⁺ permeable channels was advised as a strategy to cure glioblastoma (Alptekin et al., 2015; Ding et al., 2010; Leclerc et al., 2016; Zhang et al., 2017). The present study proposes an alternative strategy other than blocking Ca²⁺ entry; this new approach is to block the forward NCX (Ca²⁺ exit mode) and cause Ca²⁺-mediated injury in glioblastoma cells.

Bepridil and CB-DMB are inhibitors that preferentially block the forward NCX; CB-DMB is a more specific NCX blocker. SEA0400, SN-6, and YM244769 only block the reverse NCX. We show that bepridil and CB-DMB, at their concentration range for blocking the forward NCX, are toxic to glioblastoma cells. In contrast, SEA0400, SN-6, and YM244769 produce very slight toxicity to glioblastoma cells. The cytotoxicity of bepridil and CB-DMB to glioblastoma cells is likely from their blocking action on the forward NCX. In supporting this speculation, we found that both bepridil and CB-DMB incur extracellular Ca²⁺ to flow into tumour cells and thus elevates [Ca²⁺]. Bepridil or CB-DMB-caused Ca²⁺ influx results from blockade of the forward NCX. This blocking action occludes NCX-mediated Ca²⁺ exit, but extracellular Ca²⁺ can enter a cell through other Ca²⁺-permeable channels, therefore generating a net Ca²⁺ influx.

Elevation of [Ca²⁺], can modulate cell-division cycle and cell death signalling (Humeau et al., 2018). We show that both bepridil and CB-DMB can cause G₀/G₁ cell cycle arrest and apoptosis in glioblastoma cells; the Ca²⁺ chelator BAPTA-AM attenuated bepridil or CB-DMB-induced apoptosis and cell cycle arrest. These data further proved that bepridil and CB-DMB kill glioblastoma cells through blocking the forward NCX and increasing [Ca²⁺]. KB-R7943 incubation also induces G₀/G₁ arrest and apoptosis, but these cell death were not mediated by Ca²⁺ although KB-R7943 also increases [Ca²⁺]. KB-R7943 initially was reported as an inhibitor of the reverse NCX; however, there is increasing evidence that KB-R7943 also inhibits many other ionic channels (Barrientos, Bose, Peng, Padilla, & Pessah, 2009; Brustovetsky et al., 2011; Pezier, Bobkov, & Ache, 2009). In our study, KB-R7943 is also toxic to normal astrocytes at the concentration range for it suppresses glioblastoma cells. We did not conduct further study to reveal intracellular signalling that mediates toxicity of KB-R7943.

Our test of bepridil generates more encouraging results. Bepridil can penetrate the BBB and reach the brain. Animal experiment demonstrated that bepridil reduces in vivo growth of brain-grafted glioblastoma. In addition, bepridil does not produce apparent cytotoxicity to human astrocytes when it markedly inhibits glioblastoma cells in vitro. This resistance to bepridil’s cytotoxicity may result from high NCX1 expression and high NCX activity in astrocytes. The NCX1 expression is much lower in glioblastoma cells than in astrocytes. From the perspective of pharmacodynamics, the potency of a drug is proportional to the percentage of targets being occupied (Pugsley, Authier, & Curtis, 2008). When most NCX1s on glioblastoma cells are occupied by bepridil at an appropriate concentration, only a small fraction of NCX1s are blocked in astrocytes. Therefore, viability of astrocytes is not affected by bepridil when it already hurts glioblastoma cells.

The present study cannot completely exclude the possibility that other mechanisms also contribute to the sensitivity difference between astrocytes and glioblastoma cells. For example, cytosolic Na⁺ inactivates operation of the NCX1 and NCX3 (not NCX2), while increase of cytosolic Ca²⁺ activates all NCXs and also alleviates the Na⁺-induced inactivation (Tal, Kozlovska, Brisker, Giladi, & Kahanashvili, 2016; Verkhratsky, Trebak, Pirocchi, Kahanashvili, & Sekler, 2018). In glioblastoma cells, the elevated [Ca²⁺] cannot activate NCXs because most NCXs were occupied and blocked by bepridil. In human astrocytes, NCX1 is the most highly expressed isoform, and only a small portion of NCX1s were blocked by bepridil. The remaining NCX1s can be readily activated by [Ca²⁺], and operate in the forward mode, which potentially underlies astrocyte’s resistance to bepridil. Second, the reverse NCX operation accounts for [Ca²⁺] overload and ensuing injury in astrocytes when these glial cells are in resting, stimulating, or ischaemic conditions, especially when Na⁺-driven uptake of neurotransmitters occurs (Reyes, Verkhratsky, & Parpura, 2012; Verkhratsky et al., 2018). It is possible that the reverse NCXs were blocked by bepridil in human astrocytes, and thereafter, the cytotoxicity was regressed, whereas this situation is different in glioblastoma and the cytotoxicity was augmented because the forward NCXs were inhibited.

The role of NCX has been well described in glial cells by these articles (Boscia et al., 2016; Parpura, Sekler, & Fern, 2016; Rose & Verkhratsky, 2016). But there are very few studies that report NCXs in the tissue of glioblastoma; particularly, it lacks data that compare NCXs between glioblastoma and glial cells. We here got a new
observation that the NCX activity is higher in normal astrocytes than that in glioblastoma cells. The direction of NCX operation is controlled by change of membrane potential and gradients of Na$^+$ and Ca$^{2+}$, which constantly coordinate with neuronal activity. Conversely, the NCX operation tightly regulates Na$^+$ and Ca$^{2+}$ signalling, which manipulates neuronal excitability and neurotransmission. Down-regulated NCX activity in glioblastoma cells could disrupt the crosstalk between glial and neuronal cells, leading to a detrimental ionic environment in the brain. So far, our materials verify our hypothesis and suggest that the plasma membrane NCX represents a new potential therapeutic target for glioblastoma.

Glioblastoma is the most common type of glioma that arises from glial cells in the brain or spinal cord. The annual incidence rate of glioblastoma in adults is between 0.6 and 3.7 per 100,000 persons (Ostrom et al., 2018). Patients with glioblastoma usually have a mean survival rate of 3–4 months if without treatment (Krex et al., 2007; Rao, 2003). Under combined treatment of radiotherapy and chemotherapy, the median survival time with grade IV glioblastoma can be prolonged to 15 months (Wen & Reardon, 2016). Currently, there is no cure for human glioblastoma. The present pharmacological study demonstrates that blocking the forward NCX causes [Ca$^{2+}$]i accumulation and Ca$^{2+}$-mediated demise of glioblastoma cells. Bepridil is effective in degrading glioblastoma via blocking the forward NCX, thus may be used as a leading compound for developing new anti-tumour drugs. Bepridil was previously approved by the Food and Drug Administration to treat angina but withdrawn later because it can induce new arrhythmias. We recommend that a structural modification is required to reduce the cardiac side effect of bepridil before it is re-purposed to treat human glioblastoma.

ACKNOWLEDGEMENTS
This work was supported by the National Natural Science Foundation of China (81873807, 81671375, and 81473232) and Shanghai Jiao Tong University School of Medicine (SJTU-SM). We thank Dr Ying Jin and Dr Jun Mi at Shanghai Jiao Tong University School of Medicine for the instructions.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
M.S. conceived this study, designed the experiments, and wrote this manuscript. H.-J.H., S.-S.W., Y.-X.W., and Y.L. conducted the experiments and analysed the data. X.-M.F., Y.S., and L.Z. contributed the essential reagents, tools, and techniques and contributed in method modification. H.-Z.C. supervised this project.

DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BIP guidelines for Design & Analysis, Immunoblotting and Immunochemistry, and Animal Experimentation and as recommended by funding agencies, publishers, and other organizations engaged with supporting research.

ORCID
Mingke Song https://orcid.org/0000-0002-8056-0328

REFERENCES
Alexander, S. P. H., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., ... CGTP Collaborators. (2017). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology, 174(S1), S272–S359. https://doi.org/10.1002/bph.13877
Alexander, S. P. H., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., ... CGTP Collaborators. (2017). The Concise Guide to PHARMACOLOGY 2017/18: Transporters. British Journal of Pharmacology, 174, S360–S446. https://doi.org/10.1002/bph.13883
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., ... Ahiuvalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175, 407–411. https://doi.org/10.1111/bph.14112
Alptekin, M., Ergolu, S., Tutar, E., Sencan, S., Geyik, M. A., Ulasli, M., ... Camci, C. (2015). Gene expressions of TRP channels in glioblastoma multiforme and relation with survival. Tumour Biology, 36, 9209–9213. https://doi.org/10.1007/s13277-015-5577-x
Amoroso, S., De Maio, M., Russo, G. M., Catalano, A., Bassi, A., Montagnani, S., ... Annunziato, L. (1997). Pharmaceutical evidence that the activation of the Na$^+$/Ca$^{2+}$ exchanger protects C6 glioma cells during chemical hypoxia. British Journal of Pharmacology, 121, 303–309. https://doi.org/10.1038/sj.bjp.0701092
Annunziato, L., Pignataro, G., & Di Renzo, G. F. (2004). Pharmacology of brain Na$^+$/Ca$^{2+}$ exchanger: From molecular biology to therapeutic perspectives. Pharmacological Reviews, 56, 633–654. https://doi.org/10.1124/pr.56.4.5
Barrientos, G., Bose, D. D., Feng, W., Padilla, I., & Pessah, I. N. (2009). The Na$^+$/Ca$^{2+}$ exchange inhibitor 2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate (KB-R7943) also blocks ryanodine receptors type 1 (RyR1) and type 2 (RyR2) channels. Molecular Pharmacology, 76, 560–568. https://doi.org/10.1124/mol.109.057265
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T., Kool, M., ... Pfister, S. M. (2013). Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell, 24, 660–672. https://doi.org/10.1016/j.ccr.2013.10.006
Blaustein, M. P., Juhaszova, M., Golovina, V. A., Church, P. J., & Stanley, E. F. (2002). Na/Ca exchanger and PMCA localization in neurons and astrocytes: Functional implications. Annals of the new York Academy of Sciences, 976, 356–366.
Boscia, F., Begum, G., Pignataro, G., Sirabella, R., Cuomo, O., Casamassa, A., ... Annunziato, L. (2016). Glial Na$^+$-dependent ion transporters in pathophysiological conditions. Glia, 64, 1677–1697. https://doi.org/10.1002/glia.23030
Brustovetsky, T., Brittain, M. K., Sheets, P. L., Cummins, T. R., Pinelis, V., & Brustovetsky, N. (2011). KB-R7943, an inhibitor of the reverse Na$^+$/Ca$^{2+}$ exchanger, blocks N-methyl-D-aspartate receptor and inhibits mitochondrial complex I. British Journal of Pharmacology, 162, 255–270. https://doi.org/10.1111/j.1476-5381.2010.01054.x
Buckingham, S. C., Campbell, S. L., Haas, B. R., Montana, V., Robel, S., Ogunrinu, T., & Sontheimer, H. (2011). Glutamate release by primary brain tumors induces epileptic activity. *Nature Medicine*, 17, 1269–1274. https://doi.org/10.1038/nm.2453

Cheng, H., Zhang, Y., Du, C., Dempsey, C. E., & Hancock, J. C. (2012). High potency inhibition of hERG potassium channels by the sodium–calcium exchange inhibitor KB-R7943. *British Journal of Pharmacology*, 165, 2260–2273. https://doi.org/10.1111/j.1476-5381.2011.01688.x

Ding, X., He, Z., Zhou, K., Cheng, J., Yao, H., Lu, D., ... Wang, Y. (2010). Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. *Journal of the National Cancer Institute*, 102, 1052–1068. https://doi.org/10.1093/jnci/djq217

Dong, Z., Saikumar, P., Weinberg, J. M., & Venkatachalam, M. A. (2006). Calcium in cell injury and death. *Annual Review of Pathology*, 1, 405–434. https://doi.org/10.1146/annurev.pathol.1.110304.100218

Giladi, M., Tal, I., & Khananshvili, D. (2016). Structural features of ion transport and allosteric regulation in sodium–calcium (NCX) proteins. *Frontiers in Physiology*, 7, 30.

Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., ... NC-UPHAR. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic Acids Research*, 46, D1091–D1106. https://doi.org/10.1093/nar/gkx1121

Herchuelz, A., Kamagate, A., Xenimes, H., & Van Eylen, F. (2007). Role of Na/Ca exchange and the plasma membrane Ca²⁺-ATPase in β cell function and death. *Annals of the new York Academy of Sciences*, 1099, 456–467. https://doi.org/10.1196/annals.1387.048

Hsu, L. S., Chow, W. Y., & Chueh, S. H. (1995). Evidence for a Na⁺/Ca²⁺ exchanger in neuroblastoma × glioma hybrid NG108-15 cells. *The Biochemical Journal*, 309(Pt 2), 445–452. https://doi.org/10.1042/bj3090445

Hsu, S. S., Chow, C. T., Liao, W. C., Shiieh, P., Kuo, D. H., Kuo, C. C., ... Liang, W. Z. (2016). The effect of gallic acid on cytotoxicity, Ca²⁺ homeostasis, and associated receptors in malignant brain tumor therapy. *Molecular Pharmacology*, 90, 403–409. https://doi.org/10.1124/mol.116.103777

Nagy, Z. A., Virag, L., Toth, A., Biliczki, P., Ascal, K., Banyasz, T., ... Varró, A. (2004). Selective inhibition of sodium–calcium exchanger by SEA-0400 decreases early and delayed after depolarization in canine heart. *British Journal of Pharmacology*, 143, 827–831. https://doi.org/10.1038/sj.bjp.0706026

Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S., & Barnholtz-Sloan, J. S. (2018). Epidemiology of intracranial gliomas. *Progress in Neurological Surgery*, 30, 1–11. https://doi.org/10.1159/000464374

Pappalardo, L. W., Samad, O. A., Black, J. A., & Waxman, S. G. (2014). Voltage-gated sodium channel Na1.5 contributes to astrogliosis in an in vitro model of glial injury via reverse Na⁺/Ca²⁺ exchange. *Glia*, 62, 1162–1175. https://doi.org/10.1002/glia.22671

Parpura, V., Sekler, I., & Kern, F. (2016). Plasminemmal and mitochondrial Na⁺–Ca²⁺ exchange in neuroglia. *Glia*, 64, 1646–1654. https://doi.org/10.1002/glia.22975

Pezier, A., Bobkov, Y. V., & Ache, B. W. (2009). The Na+/Ca²⁺ exchanger 3 (NCX3) gene leads to a worsening of ischemic brain damage. *The Journal of Neuroscience*, 28, 1179–1184. https://doi.org/10.1523/JNEUROSCI.4671-07.2008

Pignataro, G., Gala, R., Cuomo, O., Tortiglione, A., Giaccio, L., Castaldo, P., ... Ache, B. W. (2009). The Na+/Ca²⁺ exchanger 3 (NCX3) gene leads to a worsening of ischemic brain damage. *The Journal of Neuroscience*, 28, 1179–1184. https://doi.org/10.1523/JNEUROSCI.4671-07.2008

Pignataro, G. (2004). Selective inhibition of sodium–calcium exchanger by SEA-0400 decreases early and delayed after depolarization in canine heart. *British Journal of Pharmacology*, 143, 827–831. https://doi.org/10.1038/sj.bjp.0706026

Pignataro, G., Gala, R., Cuomo, O., Tortiglione, A., Giaccio, L., Castaldo, P., ... Ache, B. W. (2009). The Na+/Ca²⁺ exchanger 3 (NCX3) gene leads to a worsening of ischemic brain damage. *The Journal of Neuroscience*, 28, 1179–1184. https://doi.org/10.1523/JNEUROSCI.4671-07.2008
a model of allergen-induced hyperresponsiveness. Acta Physiologica (Oxford, England), 205, 279–291. https://doi.org/10.1111/j.1748-1716.2011.02401.x

Rao, J. S. (2003). Molecular mechanisms of glioma invasiveness: The role of proteases. Nature Reviews. Cancer, 3, 489–501. https://doi.org/10.1038/nrc1121

Reyes, R. C., Verkhratsky, A., & Parpura, V. (2012). Plasmalemmal Na+/Ca2+ exchanger modulates Ca2+-dependent exocytotic release of glutamate from rat cortical astrocytes. ASN Neuro, 4, AN20110059. https://doi.org/10.1042/AN20110059

Rose, C. R., & Verkhratsky, A. (2016). Principles of sodium homeostasis and sodium signalling in astroglia. Glia, 64, 1611–1627. https://doi.org/10.1002/glia.22964

Shenoda, B. (2015). The role of Na+/Ca2+ exchanger subtypes in neuronal ischemic injury. Translational Stroke Research, 6, 181–190. https://doi.org/10.1007/s12975-015-0395-9

Song, M., Chen, D., & Yu, S. P. (2014). The TRPC channel blocker SKF 96365 inhibits glioblastoma cell growth by enhancing reverse mode of the Na+/Ca2+ exchanger and increasing intracellular Ca2+. British Journal of Pharmacology, 171, 3432–3447. https://doi.org/10.1111/bph.12691

Tal, I., Kozlovsky, T., Brisker, D., Giladi, M., & Khananshvili, D. (2016). Kinetic and equilibrium properties of regulatory Ca2+-binding domains in sodium–calcium exchangers 2 and 3. Cell Calcium, 59, 181–188. https://doi.org/10.1016/j.cca.2016.01.008

Trump, B. F., & Berezesky, I. K. (1995). Calcium-mediated cell injury and cell death. The FASEB Journal, 9, 219–228. https://doi.org/10.1096/fasebj.9.2.7781924

Verkhratsky, A., Trebak, M., Percocchi, F., Khananshvili, D., & Sekler, I. (2018). Crosslink between calcium and sodium signalling. Experimental Physiology, 103, 157–169. https://doi.org/10.1113/EP086534

Wang, J. C., Kiyosue, T., Kiriyama, K., & Arita, M. (1999). Bepridil differentially inhibits two delayed rectifier K+ currents, I\textsubscript{K,C} and I\textsubscript{K4}, in guinea-pig ventricular myocytes. British Journal of Pharmacology, 128, 1733–1738. https://doi.org/10.1038/sj.bjp.0702959

Watanabe, Y., & Kimura, J. (2001). Blocking effect of bepridil on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes. Japanese Journal of Pharmacology, 85, 370–375. https://doi.org/10.1254/jjp.85.370

Watano, T., Harada, Y., Harada, K., & Nishimura, N. (1999). Effect of Na+/Ca2+ exchange inhibitor, KB-R7943 on ouabain-induced arrhythmias in guinea-pigs. British Journal of Pharmacology, 127, 1846–1850. https://doi.org/10.1038/sj.bjp.0702740

Wen, P. Y., & Reardon, D. A. (2016). Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nature Reviews. Neurology, 12, 69–70. https://doi.org/10.1038/nrneurol.2015.242

White, C. D., & Sacks, D. B. (2010). Regulation of MAP kinase signaling by calcium. Methods in Molecular Biology, 661, 151–165. https://doi.org/10.1007/978-1-60761-795-2_9

Ye, Z. C., & Sontheimer, H. (1999). Glioma cells release excitotoxic concentrations of glutamate. Cancer Research, 59, 4383–4391.

Zhang, S. J., Xie, R. F., Wan, F., Ye, F., Guo, D. S., & Lei, T. (2013). Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes. Oncology Letters, 6, 1649–1655. https://doi.org/10.3892/ol.2013.1623

Zhang, Y., Cruickshanks, N., Yuan, F., Wang, B., Pahuski, M., Wulfkuhle, J., ... Abounader, R. (2017). Targetable T-type calcium channels drive glioblastoma. Cancer Research, 77, 3479–3490. https://doi.org/10.1158/0008-5472.CAN-16-2347

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Hu H-J, Wang S-S, Wang Y-X, et al. Blockade of the forward Na+/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+-mediated cell death. Br J Pharmacol. 2019;176:2691–2707. https://doi.org/10.1111/bph.14692